have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

You are receiving this because you have an account on www.oneGRAVESvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trials And Research
Business
People
Spotlight
Happenings
Fundraising Events

Back to News & Meetings / Clinical Trials And Research

New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease

Horizon Pharma plc today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented as part of a late-breaking oral presentation at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress in Los Angeles. In addition to primary endpoint data previously announced on Feb. 28, 2019, the presentation includes new data from two secondary endpoints that show a dramatic reduction in proptosis (eye bulging) and a substantial improvement in overall response rate in patients treated with teprotumumab compared with placebo.

These data demonstrate the potential for teprotumumab as a treatment for Active TED, which currently has no U.S. Food and Drug Administration (FDA) approved treatments. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.

Source: https://ir.horizontherapeutics.com/news-releases/news-release-details/new-data-phase-3-teprotumumab-trial-optic-shows-dramatic

Disclaimer:Horizon supports the mission of oneGRAVESvoice and has provided financial support for this platform. Horizon neither owns or controls this platform, and unless expressly stated otherwise, does not have editorial control over content or responsibility for any other information or services.

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Trusted Resources Home

Evidence & Education

People & Places

News & Meetings

Videos & Visuals

Partner Pages

New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease

Related Content

Powered by

Trusted Resources Home

Evidence & Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Partner Pages

Trusted Resources: News & Meetings

Latest announcements and gatherings

New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease

Related Content

Powered by